Ym Biosciences Reports First Patient in Phase I/II Trial of Jak1/Jak2 Inhibitor, Cyt387 Enrolled...
YM BioSciences Inc. , a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that Cytopia has commenced...


